GW and Otsuka to take Sativex to Phase III for cancer pain
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals and its US licensing partner Otsuka Pharmaceuticals are to take their cannabis extract CB1 agonist Sativex Oromucosal Spray (nabiximols) into Phase III development for the treatment of pain in patients with advanced cancer after it yielded mixed results in a Phase IIb study.